This study is looking at a medication for the treatment for Idiopathic Pulmonary fibrosis which is a chronic and progressive fibrotic disease, leading to increased difficulty in breathing and decreased quality of life.

13 nights
1 visits

The medication is a small-molecule, dual selective inhibitor for patients who have idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC).

The medication's purpose is to prevent the growth of fibrotic tissue within the lung and bile ducts. This medication is also being evaluated in Phase 2 trials in patients with the condition.

The trial has been approved by an independent ethics committee and participants will be reimbursed for their time.

Call us on 1800 243 733 to discuss your eligibility today!


Biological Sex Healthy males or females
Age 18-55 years old
BMI 18-30 kg/m²
Body Weight >50 kg
Medication Not taking any
Medical History Nothing significant
Smoking History Non smokers (last 3 months)